Targeted Endoradiotherapy with Lu<sub>2</sub>O<sub>3</sub>-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image

Targeted Endoradiotherapy with Lu<sub>2</sub>O<sub>3</sub>-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image

Prostate-specific membrane antigen (PSMA) is expressed in a variety of cancer cells, while the fibroblast activation protein (FAP) is expressed in the microenvironment of tumors. Previously, we reported the ability of iPSMA and iFAP ligands to specifically target PSMA and FAP proteins, as well as th...

Full description

Bibliographic Details
Main Authors: Myrna Luna-Gutiérrez, Blanca Ocampo-García, Nallely Jiménez-Mancilla, Alejandra Ancira-Cortez, Diana Trujillo-Benítez, Tania Hernández-Jiménez, Gerardo Ramírez-Nava, Rodrigo Hernández-Ramírez, Clara Santos-Cuevas, Guillermina Ferro-Flores
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceutics
Subjects:
lutetium oxide nanoparticles
prostate-specific membrane antigen inhibitor
fibroblast activation protein inhibitor
lutetium-177
Online Access:https://www.mdpi.com/1999-4923/14/4/720

Internet

https://www.mdpi.com/1999-4923/14/4/720

Similar Items